Dendritic cells are professional antigen-presenting immune effector cells that initiate and shape adaptive immunity by taking up exogenous antigens, cross-presenting them to cd8 cytotoxic t lymphocytes, and priming T cell responses. They are also a major target for cancer immunotherapy platforms, including nanoparticles, lipid based delivery systems, alpha helical polypeptide, dna nanomachine, and receptor-specific ligands, which are designed to enhance uptake, intracellular delivery, and activation. A key functional feature is that activation can be increased by integrated metabolic and redox modulation, consistent with their role in sensing and responding to the tumor microenvironment. Recent studies highlight enhanced maturation, migration, and functional reprogramming of dendritic cells through STING agonist plus IDO1 inhibition, GM-CSF/oxidized mtDNA synergy, and mRNA neoantigen delivery. Overall, the literature emphasizes dendritic cells as central orchestrators of antitumor immunity and as a therapeutic target for improving antigen presentation and T cell priming.
Cancer immunotherapy and antigen presentation
- Dendritic cells were described as professional antigen-presenting cells that present tumor-associated antigens to naive T cells and prime T cell-mediated antitumor responses. (PMID:41812866)
- They mediate cross-presentation of exogenous tumor antigen to activate CD8+ cytotoxic T lymphocytes, a key mechanism for cancer immunotherapy. (PMID:41758201)
- A STING agonist plus IDO1 inhibitor co-delivery strategy enhanced dendritic cell activation and maturation in cancer, specifically activating type I dendritic cells. (PMID:41702511)
- The Hepa 1-6-mGM-CSF vaccine robustly activated antigen-presenting immune cells, with improved maturation and migration linked to GM-CSF and oxidized mtDNA synergy. (PMID:41947668)
- A self-adjuvanting α-helical polypeptide delivered neoantigen mRNAs into dendritic cells and activated them to eradicate tumors. (PMID:41984833)
Nanotechnology and targeted delivery
- dna nanomachine selectively targeted dendritic cells in the tumor microenvironment and reprogrammed tumor-infiltrating immune cells. (PMID:41889102)
- alpha helical polypeptide facilitated intracellular delivery into dendritic cells while simultaneously activating them for mRNA antigen processing and presentation. (PMID:41984833)
- lipid based delivery systems are being developed to target dendritic cells for cancer applications, with formulation strategies optimized for dendritic cell uptake. (PMID:41812866)
- Passive targeting with nanoparticles and active targeting via receptor-specific ligands are highlighted as approaches to improve dendritic cell engagement. (PMID:41812866)
- dc sign binding aptamer-mediated engagement was used to preferentially target tumor-infiltrating dendritic cells. (PMID:41889102)
Tumor microenvironment and immune reprogramming
- Dendritic cells were selectively targeted and functionally reprogrammed within the tumor microenvironment by a strand-displacement-enabled DNA nanomachine. (PMID:41889102)
- Copper-based nanoplatform therapy improved antitumor immunity partly through lactate metabolic reprogramming and hypoxia alleviation, consistent with enhanced dendritic cell activation. (PMID:41679436)
- Vaccine-secreted GM-CSF synergized with oxidized mtDNA to promote dendritic cell activation, supporting stronger and longer-lasting antitumor immunity. (PMID:41947668)
- Integrated metabolic and redox modulation was noted to increase dendritic cell activation, aligning with recent nanoplatform-based immunotherapy advances. (PMID:41679436)